newsfilter
← Latest News
GlobeNewswire·

RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) will present new clinical data at the 2026 Society of Interventional Oncology Annual Scientific Meeting on February 6, 2026.
  • The study abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" was led by Christopher Laing, MD of Sutter Health.
  • Research findings indicate a simplified external pressure transducer provides reliable, reproducible intra-arterial pressure measurements during TAMP procedures, with strong correlation to intravascular pressure wire measurements in a porcine model.
  • Data shows peak intra-arterial measurements are influenced by controllable variables such as catheter balloon spacing & target vessel diameter, offering opportunities for procedural optimization.
  • The presentation is scheduled for 5:45-6:00 PM ET on February 6, 2026, in the ePoster Corridor as Abstract Number 303.
  • Co-authors include Ramtin Agah, RenovoRx's Chairman & Chief Medical Officer, Robert Strasser, & Christopher Laing.
  • RenovoRx's RenovoCath device is FDA-cleared for isolating blood flow & delivering fluids to peripheral vascular sites, including temporary vessel occlusion for chemotherapeutic infusion.
  • The company generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025 & has received repeat orders from high-volume National Cancer Institute-designated centers.
  • RenovoRx is evaluating the drug-device combination candidate IAG (intra-arterial gemcitabine delivered via RenovoCath) in the ongoing Phase III TIGeR-PaC trial.
  • IAG received Orphan Drug Designation for pancreatic cancer & bile duct cancer, granting seven years of market exclusivity upon FDA approval.
  • RenovoRx is in early stages of commercializing the RenovoCath device & TAMP therapy platform while exploring further revenue-generating activities.